SCHEMBL6433918

SCHEMBL6433918

CC(C)(C)OC(=O)N1CCN([C@H]2CC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 19/20 0.73
▸ LCK P06239 7/20 0.73
▸ SRC P12931 4/20 0.73
▸ TEK Q02763 2/20 0.73
▸ KDR P35968 2/20 0.73
▸ EGFR P00533 7/20 0.67
▸ NUDT14 O95848 2/20 0.65
▸ NUDT5 Q9UKK9 2/20 0.65
▸ LYN P07948 4/20 0.64
▸ ITK Q08881 5/20 0.61
▸ TEC P42680 4/20 0.61
▸ BMX P51813 4/20 0.61
▸ TXK P42681 2/20 0.61
▸ FGFR2 P21802 2/20 0.61
▸ ABL1 P00519 2/20 0.61
▸ ERBB2 P04626 2/20 0.61
▸ FYN P06241 2/20 0.61
▸ YES1 P07947 2/20 0.61
▸ HCK P08631 2/20 0.61
▸ FGR P09769 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29763108 1.00 BTK (0.73) BTKLCKSRCTEKKDR
SCHEMBL5801409 1.00 BTK (0.73) BTKLCKSRCTEKKDR
SCHEMBL6434918 1.00 BTK (0.73) BTKLCKSRCTEKKDR
SCHEMBL30301968 0.95 BTK (0.71) BTKLCKSRCTEKKDR
SCHEMBL26103890 0.95 BTK (0.71) BTKLCKSRCTEKKDR
SCHEMBL5801559 0.95 BTK (0.69) BTKLCKSRCTEKKDR
SCHEMBL22720698 0.95 BTK (0.69) BTKLCKSRCTEKKDR
SCHEMBL22720690 0.95 BTK (0.69) BTKLCKSRCTEKKDR
SCHEMBL22720717 0.95 BTK (0.69) BTKLCKSRCTEKKDR
SCHEMBL29470248 0.95 BTK (0.69) BTKLCKSRCTEKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023072270-A1 PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF 百极弘烨(南通)医药科技有限公司 2023-05-04 — — WO disclosed
WO-2023072270-A1 PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF 百极弘烨(南通)医药科技有限公司 2023-05-04 — — WO disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885LCK 1011/4885SRC 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback